The growth of autoimmune disease diagnosis market is driven by the increasing prevalence of autoimmune diseases, rising demand for early diagnosis and treatment, and technological advancements in diagnostic tests.

According to Stratview Research, the autoimmune disease diagnosis market size was valued at USD 5.14 billion in 2022 and it is expected to reach USD 8.57 billion in 2028, growing at a CAGR of 8.84% during the forecast period.

Autoimmune diseases are a group of conditions in which the body's immune system mistakenly attacks its own tissues. These diseases can affect any part of the body, and they can range in severity from mild to life-threatening. Some of the most common autoimmune diseases include rheumatoid arthritis, lupus erythematosus, multiple sclerosis, and type 1 diabetes.

The increasing prevalence of autoimmune diseases is one of the key drivers of the growth of the autoimmune disease diagnosis market. The rising demand for early diagnosis and treatment is another key driver of the market growth. Early diagnosis of autoimmune diseases can help to prevent complications and improve the quality of life for patients. Technological advancements in diagnostic tests are also driving the growth of the market. Newer tests are more accurate and efficient than traditional tests, and they can help to diagnose autoimmune diseases earlier.

The autoimmune disease diagnosis market is segmented by product type, test, disease, end-user, and region. By product type, the market is segmented into consumables & assay kits, instruments. By test type, the market is segmented into routine laboratory tests, inflammatory markers, autoantibodies & immunologic tests, and other tests. By disease type, the market is segmented into rheumatoid arthritis, systemic lupus erythematosus, sjogren’s syndrome, thyroiditis, scleroderma, and other diseases. By end-user type, the market is segmented as clinical laboratories, hospitals, and others.

Regional Analysis

The market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest market for autoimmune disease diagnosis. This is due to the high prevalence of autoimmune diseases in the region, the availability of advanced diagnostic tests, and the high healthcare spending. Europe is the second largest market for autoimmune disease diagnosis. Asia Pacific is expected to be the fastest growing market for autoimmune disease diagnosis during the forecast period. This is due to the increasing prevalence of autoimmune diseases in the region, the rising disposable incomes, and the increasing awareness about the importance of early diagnosis and treatment.

The key players in the autoimmune disease diagnosis market are

·        Abbott Laboratories,

·        Biomérieux,

·        Trinity Biotech,

·        Bio-rad Laboratories,

·        Thermo Fisher Scientific.

These companies are focusing on developing innovative diagnostic tests and expanding their geographical reach.

The autoimmune disease diagnosis market is a highly competitive market. The key players are competing on the basis of product innovation, pricing, and customer service. The market is expected to witness new product launches and strategic partnerships in the coming years.

Overall, the global autoimmune disease diagnosis market is expected to grow at a healthy CAGR during the forecast period. The growth of the market is driven by the increasing prevalence of autoimmune diseases, rising demand for early diagnosis and treatment, and technological advancements in diagnostic tests.